FWM
JAZZ icon

Focused Wealth Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Focused Wealth Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,100
Closed -$110K – 789
2020
Q1 		$110K Hold
1,100
– – 0.03% 185
2019
Q4 		$164K Hold
1,100
– – 0.04% 180
2019
Q3 		$141K Hold
1,100
– – 0.04% 191
2019
Q2 		$157K Buy
+1,100
New +$148K 0.04% 172

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Focused Wealth Management's JAZZ Position: Q2 2020 in Review

Focused Wealth Management sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2020, closing a stake of 1,100 shares — an estimated $110K sold.

Focused Wealth Management first reported a position in JAZZ in Q2 2019 and held it in 4 quarters. The position peaked at $164K in Q4 2019. 384 funds tracked by Wall St. Rank hold JAZZ as of Q2 2020.

  • Focused Wealth Management reported no remaining Jazz Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Focused Wealth Management sold 1,100 Jazz Pharmaceuticals shares in Q2 2020, an estimated $110K.
  • Focused Wealth Management first reported a position in Jazz Pharmaceuticals in Q2 2019 and held it in 4 quarters.
  • Focused Wealth Management's Jazz Pharmaceuticals position peaked at $164K in Q4 2019.
  • 384 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2020.

Based on Focused Wealth Management's 13F filing for Q2 2020, filed 24 Jul 2020.